Dr. Carrie Wang

Dr. Carrie Wang is an experienced surgeon and pharmacologist with over 25 years of experience in the development of medical products for preclinical and early clinical stage companies.
Dr. Wang is currently vice president of preclinical development at ARC Medical Inc, a medical device company based in Vancouver, Canada. She is also involved in business development activities to license ARC’s innovative technology to corporate partners in China.
Prior to ARC, Dr. Wang directed in vivo studies at Kardium to develop the Globe PF System for atrial fibrillation which obtained CE Mark approval in June 2020. Prior to Kardium, she directed studies at Angiotech that led to the development of the first-generation drug eluting Taxus® stents with sales greater than USD 1 billion annually. At Angiotech, she was also project leader for the development of 5-FU coated central venous catheters.
At Xphase Pharmaceuticals, Inc. and PacGen Biopharmaceuticals, Corp. Dr. Wang directed due diligence activities and evaluated merger and acquisition opportunities, adding to her more than 10 years of experience in business development.
Dr. Wang has 12 years clinical experience as attending surgeon in general and laparoscopic surgery and was one of the first laparoscopic surgeons in Sichuan province.
Dr. Wang is currently President of the Chinese American BioPharmaceutical Society (CABS), a highly influential association with more than 3,000 members and 200,000 subscribers in the life sciences industry. CABS is the largest and most active Chinese biopharmaceutical association in North American. Dr. Wang has served several leadership roles within CABS Executive Council since 2009, including president-elect in 2019-2021, chair of the organization committee for 2021 BioPacific Conference and 2021 CABS Investor Forum. Dr. Wang have received 2023 CABS 10 years of extradentary leadership award.